A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate ) and Placebo in Major Depressive Disorder, sponsored by Shire. Completed at 85 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.
Among the 26 studies in Depressive Disorder, Major by Takeda, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2011, is one of 16 in phase 3, and was the 15th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages 12–17
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 17 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,262 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 580 across the 24 interventional studies, 73,904 across the 2 observational. Of the 25 that completed or were terminated, 24 (96%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Depressive Disorder, Major by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. Eligible patients will remain on their antidepressant but will be randomized to either receive supplemental SPD489 or placebo (i.e. sugar pill). The purpose of this study is to help answer the following questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SPD489 (Lisdexamfetamine dimesylate )
Drug: Placebo
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Also known as: Vyvanse
Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: 8 weeks
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
Time frame: 8 weeks
Percentage of Participants Achieving a 25% Response on the MADRS
The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).
Time frame: up to 8 weeks
Percentage of Participants Achieving a 50% Response on the MADRS
The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).
Time frame: up to 8 weeks
Percentage of Participants Achieving Remission on the MADRS
MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).
Time frame: up to 8 weeks
Mean Change From Baseline Over Time in MADRS Total Score
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
Time frame: Baseline and up to 8 weeks
Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)
The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.
Time frame: up to 8 weeks
Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)
Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
Time frame: up to 8 weeks
Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.
Time frame: up to 8 weeks
Clinical Global Impressions - Global Improvement (CGI-I)
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: up to 8 weeks
Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: up to 8 weeks
Amphetamine Cessation Symptom Assessment (ACSA)
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
Time frame: up to 8 weeks
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 |
|---|---|---|---|
| Started | 1262 | 0 | 0 |
| Completed | 896 | 0 | 0 |
| Not completed | 366 | 0 | 0 |
| Withdrew: Adverse event | 39 | 0 | 0 |
| Withdrew: Protocol violation | 29 | 0 | 0 |
| Withdrew: Withdrawal by subject | 61 | 0 | 0 |
| Withdrew: Lost to follow-up | 96 | 0 | 0 |
| Withdrew: Met bp or pulse withdrawal criteria | 22 | 0 | 0 |
| Withdrew: Other | 119 | 0 | 0 |
| Milestone | Antidepressant + Single-blind Placebo | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 |
|---|---|---|---|
| Started | 492 | 202 | 202 |
| Completed | 415 | 164 | 160 |
| Not completed | 77 | 38 | 42 |
| Withdrew: Adverse event | 9 | 10 | 11 |
| Withdrew: Protocol violation | 4 | 5 | 0 |
| Withdrew: Withdrawal by subject | 16 | 10 | 10 |
| Withdrew: Lost to follow-up | 34 | 5 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Met bp or pulse withdrawal criteria | 2 | 3 | 3 |
| Withdrew: Other | 12 | 5 | 11 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks | -6.3 (-7.6 to -4.9) | -6.1 (-7.5 to -4.8) |
Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks | -4.3 (-5.3 to -3.3) | -4.7 (-5.6 to -3.7) |
The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).
| percentage of participants | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Percentage of Participants Achieving a 25% Response on the MADRS | 65.0 | 74.5 |
The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).
| percentage of participants | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Percentage of Participants Achieving a 50% Response on the MADRS | 38.5 | 41.0 |
MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).
| percentage of participants | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Percentage of Participants Achieving Remission on the MADRS | 22.5 | 18.5 |
MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Visit 9 (Week 9) | -2.2 (-3.1 to -1.2) | -3.4 (-4.3 to -2.4) |
| Visit 10 (Week 10) | -3.8 (-4.9 to -2.7) | -4.2 (-5.3 to -3.2) |
| Visit 11 (Week 11) | -6.0 (-7.2 to -4.8) | -5.4 (-6.6 to -4.2) |
| Visit 12 (Week 12) | -6.2 (-7.4 to -5.0) | -5.6 (-6.8 to -4.4) |
| Visit 13 (Week 14) | -7.4 (-8.7 to -6.0) | -7.3 (-8.6 to -6.0) |
| Visit 14 (Week 16) | -6.3 (-7.6 to -4.9) | -6.1 (-7.5 to -4.8) |
The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \[low amount of symptom\]) to 3 (representing the least favorable response \[frequent/intense symptom\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR) | -2.6 (-3.2 to -1.9) | -2.3 (-2.9 to -1.7) |
Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Physical | 0.69 (-0.39 to 1.77) | -0.81 (-1.89 to 0.28) |
| Mental | 5.59 (3.93 to 7.25) | 6.5 (4.84 to 8.16) |
The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF) | 7.2 (4.9 to 9.5) | 7.0 (4.7 to 9.3) |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Improved | 53.3 | 55.3 |
| Not Improved | 46.2 | 44.7 |
| Not Assessed | 0.5 | 0 |
C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| percentage of participants | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| ≥1 postive suicidal ideation | 7.0 | 7.0 |
| ≥1 suicidal attempt | 0.5 | 0 |
ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.
| units on a scale | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| Amphetamine Cessation Symptom Assessment (ACSA) | 15.1 ± 10.71 | 14.7 ± 10.94 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Antidepressant + Placebo | — | 5/201 (2.5%) | 54/201 (26.9%) |
| Antidepressant + SPD489 | — | 3/201 (1.5%) | 70/201 (34.8%) |
| Event | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| VertigoEar and labyrinth disorders | 1/201 | 0/201 |
| AppendicitisInfections and infestations | 0/201 | 1/201 |
| Wound infectionInfections and infestations | 1/201 | 0/201 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/201 | 1/201 |
| LacerationInjury, poisoning and procedural complications | 1/201 | 0/201 |
| SyncopeNervous system disorders | 1/201 | 1/201 |
| Major depressionPsychiatric disorders | 1/201 | 0/201 |
| Suicide attemptPsychiatric disorders | 1/201 | 0/201 |
| AppendicectomySurgical and medical procedures | 1/201 | 0/201 |
| Event | Antidepressant + Placebo | Antidepressant + SPD489 |
|---|---|---|
| HeadacheNervous system disorders | 21/201 | 13/201 |
| Dry mouthGastrointestinal disorders | 6/201 | 19/201 |
| InsomniaPsychiatric disorders | 15/201 | 19/201 |
| Decreased appetiteMetabolism and nutrition disorders | 8/201 | 15/201 |
| NauseaGastrointestinal disorders | 10/201 | 13/201 |
| NasopharyngitisInfections and infestations | 4/201 | 11/201 |
Safety Analysis Set: All subjects who took at least 1 dose of randomized investigational product and who had at least 1 safety assessment (e.g., coming back for any visit, reporting of an adverse event \[AE\], or reporting the absence of AEs) after the Augmentation Baseline Visit (Visit 8).
| Age, Continuous(Years) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 | Total |
|---|---|---|---|
| Mean | 41.8 ± 12.04 | 42.2 ± 12.32 | 42 ± 12.17 |
| Age, Customized(Participants) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 | Total |
|---|---|---|---|
| 18-55 years | 173 | 170 | 343 |
| 56-65 years | 28 | 31 | 59 |
| Sex: Female, Male(Participants) | Antidepressant + Double-blind Placebo | Antidepressant + Double-blind SPD489 | Total |
|---|---|---|---|
| Female | 133 | 129 | 262 |
| Male | 68 | 72 | 140 |
Ran from Oct 2011 to primary completion in Dec 2013, 25 months.
Results were first posted in Nov 2014, 10 months after primary completion. A results delay was requested in Aug 2014.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 25 months is close to that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine